Oppenheimer & Co. Inc. Decreases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Oppenheimer & Co. Inc. trimmed its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 59.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 38,416 shares of the biotechnology company's stock after selling 56,522 shares during the period. Oppenheimer & Co. Inc.'s holdings in ADMA Biologics were worth $659,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics in the 3rd quarter worth $30,000. Larson Financial Group LLC bought a new stake in ADMA Biologics during the third quarter valued at about $31,000. GAMMA Investing LLC increased its position in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares in the last quarter. National Bank of Canada FI bought a new position in shares of ADMA Biologics in the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at about $62,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

ADMA traded down $0.41 on Monday, hitting $16.61. 2,441,032 shares of the company's stock traded hands, compared to its average volume of 3,325,074. The company's 50 day simple moving average is $16.66 and its 200-day simple moving average is $17.96. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a one year low of $5.88 and a one year high of $23.64. The firm has a market cap of $3.93 billion, a price-to-earnings ratio of 59.32 and a beta of 0.60.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.